Erlotinib has moderate single-agent activity in chemotherapy-naive castration-resistant prostate cancer: final results of a phase II trial
C Nabhan, TM Lestingi, A Galvez, K Tolzien, SK Kelby… - Urology, 2009 - Elsevier
OBJECTIVES: To investigate the efficacy and toxicity of single-agent erlotinib in
chemotherapy-naive castration-resistant prostate cancer. METHODS: Eligible patients …
chemotherapy-naive castration-resistant prostate cancer. METHODS: Eligible patients …
Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer
H Wu, L Zhang, X Gao, X Zhang, J Duan, L You… - Cancer letters, 2017 - Elsevier
Enzalutamide, a novel androgen receptor (AR) antagonist, prolongs overall survival of
patients with castration-resistant prostate cancer (CRPC); however, patients eventually …
patients with castration-resistant prostate cancer (CRPC); however, patients eventually …
[HTML][HTML] Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer
Incurable castration-resistant prostate cancer (CRPC) is driven by androgen receptor (AR)
activation. Potent therapies that prevent AR signaling, such as Enzalutamide (ENZ), are …
activation. Potent therapies that prevent AR signaling, such as Enzalutamide (ENZ), are …
Everolimus combined with gefitinib in patients with metastatic castration‐resistant prostate cancer: Phase 1/2 results and signaling pathway implications
BACKGROUND The effects of mammalian target of rapamycin (mTOR) inhibition are limited
by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin …
by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin …
[HTML][HTML] CREB5 promotes resistance to androgen-receptor antagonists and androgen deprivation in prostate cancer
JH Hwang, JH Seo, ML Beshiri, S Wankowicz, D Liu… - Cell Reports, 2019 - cell.com
Summary Androgen-receptor (AR) inhibitors, including enzalutamide, are used for treatment
of all metastatic castration-resistant prostate cancers (mCRPCs). However, some patients …
of all metastatic castration-resistant prostate cancers (mCRPCs). However, some patients …
A phase I/II trial of enzalutamide plus the glucocorticoid receptor antagonist mifepristone for patients with metastatic castration-resistant prostate cancer (mCRPC).
RZ Szmulewitz, C Nabhan, PH O'Donnell, J Kach… - 2016 - ascopubs.org
TPS5091 Background: Metastatic castration-resistant prostate cancer (mCRPC) is a lethal
disease with limited therapeutic options. AR targeting therapies such as enzalutamide (Enz) …
disease with limited therapeutic options. AR targeting therapies such as enzalutamide (Enz) …
[HTML][HTML] Breaking through resistance in mCRPC: Enzalutamide analogues as effective anticancer agents for enhanced male survival
To alleviate metastatic castration-resistant prostate cancer (mCRPC), enzalutamide, a non-
steroidal antiandrogen, is employed. Following androgen deprivation therapy or anti …
steroidal antiandrogen, is employed. Following androgen deprivation therapy or anti …
Androgen receptor antagonists in castration-resistant prostate cancer
D Rathkopf, HI Scher - The Cancer Journal, 2013 - journals.lww.com
Persistent androgen receptor (AR) signaling despite low levels of serum androgens has
been identified as a critical target for drug discovery in castration-resistant prostate cancer …
been identified as a critical target for drug discovery in castration-resistant prostate cancer …
Phase I/II trial of enzalutamide (Enz) plus mifepristone (Mif) for metastatic castration-resistant prostate cancer (mCRPC).
A Serritella, DH Shevrin, EI Heath, JL Wade, E Martinez… - 2020 - ascopubs.org
91 Background: Resistance to androgen receptor (AR) targeted therapies is common in
mCRPC. Glucocorticoid receptor (GR) expression increases with AR inhibition in patients …
mCRPC. Glucocorticoid receptor (GR) expression increases with AR inhibition in patients …
New therapies for castration-resistant prostate cancer: efficacy and safety
Abstract Context Prostate cancer (PCa) is the most common noncutaneous malignancy and
the second leading cause of cancer mortality amongst men in the Western world. Up to 40 …
the second leading cause of cancer mortality amongst men in the Western world. Up to 40 …